vTv Therapeutics VTVT Stock
vTv Therapeutics Price Chart
vTv Therapeutics VTVT Financial and Trading Overview
| vTv Therapeutics stock price | 32 USD |
| Previous Close | 32.36 USD |
| Open | 31.88 USD |
| Bid | 31.5 USD x 300 |
| Ask | 32.8 USD x 100 |
| Day's Range | 31.35 - 32.22 USD |
| 52 Week Range | 17 - 44 USD |
| Volume | 94.15K USD |
| Avg. Volume | 74.03K USD |
| Market Cap | 126.53M USD |
| Beta (5Y Monthly) | 0.289 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.75 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 53.83 USD |
VTVT Valuation Measures
| Enterprise Value | 310.94M USD |
| Trailing P/E | N/A |
| Forward P/E | -7.609988 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 3.4345584 |
| Price/Book (mrq) | 5.050505 |
| Enterprise Value/Revenue | 8.441 |
| Enterprise Value/EBITDA | -33.634 |
Trading Information
vTv Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.289 |
| 52-Week Change | 75.86% |
| S&P500 52-Week Change | 20.20% |
| 52 Week High | 44 USD |
| 52 Week Low | 17 USD |
| 50-Day Moving Average | 33.26 USD |
| 200-Day Moving Average | 34.32 USD |
VTVT Share Statistics
| Avg. Volume (3 month) | 74.03K USD |
| Avg. Daily Volume (10-Days) | 56.42K USD |
| Shares Outstanding | 3.95M |
| Float | 2.16M |
| Short Ratio | 1.54 |
| % Held by Insiders | 38.82% |
| % Held by Institutions | 40.74% |
| Shares Short | 166K |
| Short % of Float | 6.91% |
| Short % of Shares Outstanding | 4.20% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:40 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -12.91% |
| Operating Margin (ttm) | -25.11% |
| Gross Margin | 22.15% |
| EBITDA Margin | -25.096% |
Management Effectiveness
| Return on Assets (ttm) | -10.14% |
| Return on Equity (ttm) | -15.80% |
Income Statement
| Revenue (ttm) | 36.84M USD |
| Revenue Per Share (ttm) | 3.25 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 8.16M USD |
| EBITDA | -9245000 USD |
| Net Income Avi to Common (ttm) | -4756000 USD |
| Diluted EPS (ttm) | -0.75 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 86.64M USD |
| Total Cash Per Share (mrq) | 6.97 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 12.482 |
| Book Value Per Share (mrq) | 6.336 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -16762000 USD |
| Levered Free Cash Flow (ttm) | 674.38K USD |
Profile of vTv Therapeutics
| Country | United States |
| State | NC |
| City | High Point |
| Address | 3980 Premier Drive |
| ZIP | 27265 |
| Phone | 336 841 0300 |
| Website | https://vtvtherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 26 |
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.
Q&A For vTv Therapeutics Stock
What is a current VTVT stock price?
vTv Therapeutics VTVT stock price today per share is 32 USD.
How to purchase vTv Therapeutics stock?
You can buy VTVT shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for vTv Therapeutics?
The stock symbol or ticker of vTv Therapeutics is VTVT.
Which industry does the vTv Therapeutics company belong to?
The vTv Therapeutics industry is Biotechnology.
How many shares does vTv Therapeutics have in circulation?
The max supply of vTv Therapeutics shares is 3.95M.
What is vTv Therapeutics Price to Earnings Ratio (PE Ratio)?
vTv Therapeutics PE Ratio is now.
What was vTv Therapeutics earnings per share over the trailing 12 months (TTM)?
vTv Therapeutics EPS is -0.75 USD over the trailing 12 months.
Which sector does the vTv Therapeutics company belong to?
The vTv Therapeutics sector is Healthcare.
vTv Therapeutics VTVT included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26370.89 USD — |
-0.12
|
6.86B USD — | 26249.77 USD — | 26398.33 USD — | — - | 6.86B USD — |
|
US Tech Composite Total Return
XCMP
US
|
32552.9 USD — |
-0.12
|
— — | 32403.39 USD — | 32586.77 USD — | — - | — — |
|
US Tech Capital Market Composite
RCMP
US
|
139.67 USD — |
-0.33
|
— — | 138.52 USD — | 139.84 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1340.2 USD — |
+0.03
|
— — | 1322.75 USD — | 1344.13 USD — | — - | — — |
- {{ link.label }} {{link}}
